COMPASS PATHWAYS PLC (CMPS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CMPS • US20451W1018

6.615 USD
+0 (+0.08%)
Last: Feb 3, 2026, 03:38 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMPS. CMPS was compared to 524 industry peers in the Biotechnology industry. Both the profitability and financial health of CMPS have multiple concerns. CMPS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • CMPS had negative earnings in the past year.
  • CMPS had a negative operating cash flow in the past year.
  • CMPS had negative earnings in each of the past 5 years.
  • CMPS had a negative operating cash flow in each of the past 5 years.
CMPS Yearly Net Income VS EBIT VS OCF VS FCFCMPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -92.84%, CMPS is doing worse than 73.66% of the companies in the same industry.
  • CMPS has a Return On Equity of -631.31%. This is in the lower half of the industry: CMPS underperforms 76.72% of its industry peers.
Industry RankSector Rank
ROA -92.84%
ROE -631.31%
ROIC N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
CMPS Yearly ROA, ROE, ROICCMPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CMPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPS Yearly Profit, Operating, Gross MarginsCMPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CMPS has more shares outstanding
  • Compared to 5 years ago, CMPS has more shares outstanding
  • Compared to 1 year ago, CMPS has a worse debt to assets ratio.
CMPS Yearly Shares OutstandingCMPS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CMPS Yearly Total Debt VS Total AssetsCMPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • CMPS has an Altman-Z score of -4.42. This is a bad value and indicates that CMPS is not financially healthy and even has some risk of bankruptcy.
  • CMPS has a Altman-Z score (-4.42) which is in line with its industry peers.
  • CMPS has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of CMPS (0.49) is worse than 70.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -4.42
ROIC/WACCN/A
WACCN/A
CMPS Yearly LT Debt VS Equity VS FCFCMPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • CMPS has a Current Ratio of 1.23. This is a normal value and indicates that CMPS is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CMPS (1.23) is worse than 83.78% of its industry peers.
  • CMPS has a Quick Ratio of 1.23. This is a normal value and indicates that CMPS is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of CMPS (1.23) is worse than 82.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
CMPS Yearly Current Assets VS Current LiabilitesCMPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

  • CMPS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.00%.
EPS 1Y (TTM)-30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CMPS will show a small growth in Earnings Per Share. The EPS will grow by 7.15% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.79%
EPS Next 2Y12.26%
EPS Next 3Y10.35%
EPS Next 5Y7.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPS Yearly Revenue VS EstimatesCMPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B
CMPS Yearly EPS VS EstimatesCMPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • CMPS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CMPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPS Price Earnings VS Forward Price EarningsCMPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPS Per share dataCMPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.26%
EPS Next 3Y10.35%

More info and screens

0

5. Dividend

5.1 Amount

  • CMPS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

COMPASS PATHWAYS PLC

NASDAQ:CMPS (2/3/2026, 3:38:33 PM)

6.615

+0 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-25
Inst Owners61.75%
Inst Owner Change-0.25%
Ins Owners1.76%
Ins Owner Change0%
Market Cap618.91M
Revenue(TTM)N/A
Net Income(TTM)-237.32M
Analysts83.53
Price Target17.15 (159.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-127.95%
Min EPS beat(2)-261.99%
Max EPS beat(2)6.08%
EPS beat(4)3
Avg EPS beat(4)-58.32%
Min EPS beat(4)-261.99%
Max EPS beat(4)20.36%
EPS beat(8)4
Avg EPS beat(8)-37.83%
EPS beat(12)6
Avg EPS beat(12)-28.62%
EPS beat(16)9
Avg EPS beat(16)-17.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-66.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.46
P/tB 16.46
EV/EBITDA N/A
EPS(TTM)-2.86
EYN/A
EPS(NY)-1.7
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.84%
ROE -631.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -4.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.7%
Cap/Depr(5y)102.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
EPS Next Y-8.79%
EPS Next 2Y12.26%
EPS Next 3Y10.35%
EPS Next 5Y7.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.37%
EBIT Next 3Y-0.39%
EBIT Next 5Y8.7%
FCF growth 1Y-40.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.69%
OCF growth 3YN/A
OCF growth 5YN/A

COMPASS PATHWAYS PLC / CMPS FAQ

What is the fundamental rating for CMPS stock?

ChartMill assigns a fundamental rating of 1 / 10 to CMPS.


What is the valuation status of COMPASS PATHWAYS PLC (CMPS) stock?

ChartMill assigns a valuation rating of 0 / 10 to COMPASS PATHWAYS PLC (CMPS). This can be considered as Overvalued.


What is the profitability of CMPS stock?

COMPASS PATHWAYS PLC (CMPS) has a profitability rating of 0 / 10.


Can you provide the financial health for CMPS stock?

The financial health rating of COMPASS PATHWAYS PLC (CMPS) is 2 / 10.